CD274 and hepatocellular carcinoma: In addition, the Phase II clinical trial (NCT05441475) results for ABSK011 in combination with the anti-PD-L1 antibody Atezolizumab for advanced HCC patients were presented at the 2024 ESMO-GI Congress by Abbisko Therapeutics.